Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone De
Go back to Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone De| Asianada, Inc. (NASDAQ: ASND) | Delayed: 262.25 -7.84 (2.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $270.09 | 52 Week High | $21.79 | |||
| Open | $270.89 | 52 Week Low | $11.92 | |||
| Day High | $272.37 | P/E | N/A | |||
| Day Low | $262.11 | EPS | $-0.07 | |||
| Volume | 251,679 | |||||
